Company: INMB
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001013762-25-003354
Chunk: 366

Company: Inmune Bio, Inc.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 1C
Chunk 366
---
the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond
to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements.
Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating
the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

Critical Audit Matters

Critical audit matters are matters arising from
the current period audit of the financial statements that were communicated or required to be communicated to the audit committee and
that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging,
subjective, or complex judgments. We determined that there are no critical audit matters.

/s/ Marcum LLP

Marcum LLP

We have served as the Company’s auditor since 2017.

Houston, Texas

March 27, 2025

F-2

INMUNE BIO INC. 

CONSOLIDATED BALANCE SHEETS

(In thousands, except share and per share amounts)

    December 31, 2024  
    December 31, 2023 
  
    ASSETS 

    CURRENT ASSETS 

    Cash and cash equivalents 
    $20,922  
    $35,848 
  
    Research and development tax credit receivable 
     1,181  
     1,905 
  
    Other tax receivable 
     228  
     537 
  
    Prepaid expenses and other current assets 
     331  
     1,510 
  
    Prepaid expenses – related party 
     -  
     142 
  
    TOTAL CURRENT ASSETS 
     22,662  
     39,942 

    Operating lease – right of use asset 
     307  
     414 
  
    Other assets 
     79  
     131 
  
    Acquired in-process research and development intangible assets 
     16,514  
     16,514 

    TOTAL ASSETS 
    $39,562  
    $57,001 

    LIABILITIES, REDEEMABLE COMMON STOCK AND STOCKHOLDERS’ EQUITY 

    CURRENT LIABILITIES 

    Accounts payable and accrued liabilities 
    $6,539  
    $7,901 
  
    Accounts payable